Alteration of LARGE1 abundance in patients and a mouse model of 5q-associated spinal muscular atrophy.
CSF
Proteomics
SMA
Serum
Skeletal muscle
Spinal cord
Journal
Acta neuropathologica
ISSN: 1432-0533
Titre abrégé: Acta Neuropathol
Pays: Germany
ID NLM: 0412041
Informations de publication
Date de publication:
12 Mar 2024
12 Mar 2024
Historique:
received:
16
11
2023
accepted:
16
02
2024
revised:
16
02
2024
medline:
12
3
2024
pubmed:
12
3
2024
entrez:
12
3
2024
Statut:
epublish
Résumé
Spinal muscular atrophy (SMA) is a neuromuscular disorder caused by recessive pathogenic variants affecting the survival of motor neuron (SMN1) gene (localized on 5q). In consequence, cells lack expression of the corresponding protein. This pathophysiological condition is clinically associated with motor neuron (MN) degeneration leading to severe muscular atrophy. Additionally, vulnerability of other cellular populations and tissues including skeletal muscle has been demonstrated. Although the therapeutic options for SMA have considerably changed, treatment responses may differ thus underlining the persistent need for validated biomarkers. To address this need and to identify novel marker proteins for SMA, we performed unbiased proteomic profiling on cerebrospinal fluid derived (CSF) from genetically proven SMA type 1-3 cases and afterwards performed ELISA studies on CSF and serum samples to validate the potential of a novel biomarker candidates in both body fluids. To further decipher the pathophysiological impact of this biomarker, immunofluorescence studies were carried out on spinal cord and skeletal muscle derived from a 5q-SMA mouse model. Proteomics revealed increase of LARGE1 in CSF derived from adult patients showing a clinical response upon treatment with nusinersen. Moreover, LARGE1 levels were validated in CSF samples of further SMA patients (type 1-3) by ELISA. These studies also unveiled a distinguishment between groups in improvement of motor skills: adult patients do present with lowered level per se at baseline visit while no elevation upon treatment in the pediatric cohort can be observed. ELISA-based studies of serum samples showed no changes in the pediatric cohort but unraveled elevated level in adult patients responding to future intervention with nusinersen, while non-responders did not show a significant increase. Additional immunofluorescence studies of LARGE1 in MN and skeletal muscle of a SMA type 3 mouse model revealed an increase of LARGE1 during disease progression. Our combined data unraveled LARGE1 as a protein dysregulated in serum and CSF of SMA-patients (and in MN and skeletal muscle of SMA mice) holding the potential to serve as a disease marker for SMA and enabling to differentiate between patients responding and non-responding to therapy with nusinersen.
Identifiants
pubmed: 38470509
doi: 10.1007/s00401-024-02709-x
pii: 10.1007/s00401-024-02709-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
53Informations de copyright
© 2024. The Author(s).
Références
Beaudin M, Kamali T, Tang W, Hagerman KA, Dunaway Young S, Ghiglieri L et al (2023) Cerebrospinal fluid proteomic changes after nusinersen in patients with spinal muscular atrophy. J Clin Med. https://doi.org/10.3390/jcm12206696
doi: 10.3390/jcm12206696
pubmed: 37892834
pmcid: 10607664
Callister SJ, Barry RC, Adkins JN, Johnson ET, Qian WJ, Webb-Robertson BJ et al (2006) Normalization approaches for removing systematic biases associated with mass spectrometry and label-free proteomics. J Proteome Res 5:277–286. https://doi.org/10.1021/pr050300l
doi: 10.1021/pr050300l
pubmed: 16457593
pmcid: 1992440
Chiriboga CA, Swoboda KJ, Darras BT, Iannaccone ST, Montes J, De Vivo DC et al (2016) Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology 86:890–897. https://doi.org/10.1212/WNL.0000000000002445
doi: 10.1212/WNL.0000000000002445
pubmed: 26865511
pmcid: 4782111
Crawford TO, Pardo CA (1996) The neurobiology of childhood spinal muscular atrophy. Neurobiol Dis 3:97–110. https://doi.org/10.1006/nbdi.1996.0010
doi: 10.1006/nbdi.1996.0010
pubmed: 9173917
D’Amico D, Biondi O, Januel C, Bezier C, Sapaly D, Clerc Z et al (2022) Activating ATF6 in spinal muscular atrophy promotes SMN expression and motor neuron survival through the IRE1alpha-XBP1 pathway. Neuropathol Appl Neurobiol 48:e12816. https://doi.org/10.1111/nan.12816
doi: 10.1111/nan.12816
pubmed: 35338505
De Vivo DC, Bertini E, Swoboda KJ, Hwu WL, Crawford TO, Finkel RS et al (2019) Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 nurture study. Neuromuscul Disord 29:842–856. https://doi.org/10.1016/j.nmd.2019.09.007
doi: 10.1016/j.nmd.2019.09.007
pubmed: 31704158
pmcid: 7127286
De Wel B, De Schaepdryver M, Poesen K, Claeys KG (2022) Biochemical and clinical biomarkers in adult SMA 3–4 patients treated with nusinersen for 22 months. Ann Clin Transl Neurol 9:1241–1251. https://doi.org/10.1002/acn3.51625
doi: 10.1002/acn3.51625
pubmed: 35833245
pmcid: 9380134
Dhillon S (2020) Risdiplam: first approval. Drugs 80:1853–1858. https://doi.org/10.1007/s40265-020-01410-z
doi: 10.1007/s40265-020-01410-z
pubmed: 33044711
Faravelli I, Meneri M, Saccomanno D, Velardo D, Abati E, Gagliardi D et al (2020) Nusinersen treatment and cerebrospinal fluid neurofilaments: an explorative study on spinal muscular atrophy type 3 patients. J Cell Mol Med 24:3034–3039. https://doi.org/10.1111/jcmm.14939
doi: 10.1111/jcmm.14939
pubmed: 32032473
pmcid: 7077557
Filezac de L’Etang A, Maharjan N, Cordeiro Brana M, Ruegsegger C, Rehmann R, Goswami A et al (2015) Marinesco-Sjogren syndrome protein SIL1 regulates motor neuron subtype-selective ER stress in ALS. Nat Neurosci 18:227–238. https://doi.org/10.1038/nn.3903
doi: 10.1038/nn.3903
pubmed: 25559081
Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J et al (2017) Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 377:1723–1732. https://doi.org/10.1056/NEJMoa1702752
doi: 10.1056/NEJMoa1702752
pubmed: 29091570
Francini-Pesenti F, Vitturi N, Tresso S, Soraru G (2020) Metabolic alterations in spinal and bulbar muscular atrophy. Rev Neurol (Paris) 176:780–787. https://doi.org/10.1016/j.neurol.2020.03.020
doi: 10.1016/j.neurol.2020.03.020
pubmed: 32631678
Gumerson JD, Davis CS, Kabaeva ZT, Hayes JM, Brooks SV, Michele DE (2013) Muscle-specific expression of LARGE restores neuromuscular transmission deficits in dystrophic LARGE(myd) mice. Hum Mol Genet 22:757–768. https://doi.org/10.1093/hmg/dds483
doi: 10.1093/hmg/dds483
pubmed: 23222475
Hensel N, Kubinski S, Claus P (2020) The need for SMN-independent treatments of spinal muscular atrophy (SMA) to complement SMN-enhancing drugs. Front Neurol 11:45. https://doi.org/10.3389/fneur.2020.00045
doi: 10.3389/fneur.2020.00045
pubmed: 32117013
pmcid: 7009174
Kelstrup CD, Young C, Lavallee R, Nielsen ML, Olsen JV (2012) Optimized fast and sensitive acquisition methods for shotgun proteomics on a quadrupole orbitrap mass spectrometer. J Proteome Res 11:3487–3497. https://doi.org/10.1021/pr3000249
doi: 10.1021/pr3000249
pubmed: 22537090
Kotecha U, Mistri M, Shah N, Shah PS, Gupta VA (2021) Bi-allelic loss of function variants in GOLGA2 are associated with a complex neurological phenotype: Report of a second family. Clin Genet 100:748–751. https://doi.org/10.1111/cge.14053
doi: 10.1111/cge.14053
pubmed: 34424553
Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L et al (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80:155–165. https://doi.org/10.1016/0092-8674(95)90460-3
doi: 10.1016/0092-8674(95)90460-3
pubmed: 7813012
Leo M, Schmitt LI, Fleischer M, Steffen R, Osswald C, Kleinschnitz C et al (2022) Induction of survival of motor neuron (SMN) protein deficiency in spinal astrocytes by small interfering RNA as an In Vitro model of spinal muscular atrophy. Cells. https://doi.org/10.3390/cells11030558
doi: 10.3390/cells11030558
pubmed: 36552757
pmcid: 9776412
Lorson CL, Androphy EJ (2000) An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN. Hum Mol Genet 9:259–265. https://doi.org/10.1093/hmg/9.2.259
doi: 10.1093/hmg/9.2.259
pubmed: 10607836
Meilleur KG, Zukosky K, Medne L, Fequiere P, Powell-Hamilton N, Winder TL et al (2014) Clinical, pathologic, and mutational spectrum of dystroglycanopathy caused by large mutations. J Neuropathol Exp Neurol 73:425–441. https://doi.org/10.1097/NEN.0000000000000065
doi: 10.1097/NEN.0000000000000065
pubmed: 24709677
Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW et al (2017) Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 377:1713–1722. https://doi.org/10.1056/NEJMoa1706198
doi: 10.1056/NEJMoa1706198
pubmed: 29091557
Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM et al (2018) Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med 378:625–635. https://doi.org/10.1056/NEJMoa1710504
doi: 10.1056/NEJMoa1710504
pubmed: 29443664
Niu SP, Zhang YJ, Han N, Yin XF, Zhang DY, Kou YH (2021) Identification of four differentially expressed genes associated with acute and chronic spinal cord injury based on bioinformatics data. Neural Regen Res 16:865–870. https://doi.org/10.4103/1673-5374.297087
doi: 10.4103/1673-5374.297087
pubmed: 33229721
Olsson B, Alberg L, Cullen NC, Michael E, Wahlgren L, Kroksmark AK et al (2019) NFL is a marker of treatment response in children with SMA treated with nusinersen. J Neurol 266:2129–2136. https://doi.org/10.1007/s00415-019-09389-8
doi: 10.1007/s00415-019-09389-8
pubmed: 31123861
pmcid: 6687695
Petzold A (2005) Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 233:183–198. https://doi.org/10.1016/j.jns.2005.03.015
doi: 10.1016/j.jns.2005.03.015
pubmed: 15896809
Schorling DC, Kolbel H, Hentschel A, Pechmann A, Meyer N, Wirth B et al (2022) Cathepsin D as biomarker in cerebrospinal fluid of nusinersen-treated patients with spinal muscular atrophy. Eur J Neurol 29:2084–2096. https://doi.org/10.1111/ene.15331
doi: 10.1111/ene.15331
pubmed: 35318785
Schorling DC, Pechmann A, Kirschner J (2020) Advances in treatment of spinal muscular atrophy—new phenotypes, new challenges, new implications for care. J Neuromuscul Dis 7:1–13. https://doi.org/10.3233/JND-190424
doi: 10.3233/JND-190424
pubmed: 31707373
pmcid: 7029319
Smeriglio P, Langard P, Querin G, Biferi MG (2020) The identification of novel biomarkers is required to improve adult SMA patient stratification, diagnosis and treatment. J Pers Med. https://doi.org/10.3390/jpm10030075
doi: 10.3390/jpm10030075
pubmed: 32751151
pmcid: 7564782
Spicer C, Lu CH, Catapano F, Scoto M, Zaharieva I, Malaspina A et al (2021) The altered expression of neurofilament in mouse models and patients with spinal muscular atrophy. Ann Clin Transl Neurol 8:866–876. https://doi.org/10.1002/acn3.51336
doi: 10.1002/acn3.51336
pubmed: 33683023
pmcid: 8045929
Totzeck A, Stolte B, Kizina K, Bolz S, Schlag M, Thimm A et al (2019) Neurofilament heavy chain and tau protein are not elevated in cerebrospinal fluid of adult patients with spinal muscular atrophy during loading with nusinersen. Int J Mol Sci. https://doi.org/10.3390/ijms20215397
doi: 10.3390/ijms20215397
pubmed: 31671515
pmcid: 6862027
Yuan A, Rao MV, Veeranna NRA (2017) Neurofilaments and neurofilament proteins in health and disease. Cold Spring Harb Perspect Biol. https://doi.org/10.1101/cshperspect.a018309
doi: 10.1101/cshperspect.a018309
pubmed: 28373358
pmcid: 5378049